An Ongoing Phase 1 Study of ABT-263; Pharmacokineties, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Roberts, Andrew W. [1 ]
Brown, Jennifer [2 ]
Seymour, John F. [3 ]
Wierda, William G. [4 ]
Kipps, Thomas J. [5 ]
Xiong, Hao [6 ]
Chiu, Yi-Lin [6 ]
Busman, Todd [6 ]
Knight, Raymond A. [6 ]
Enschede, Sari [6 ]
Krivoshik, Andrew [6 ]
Humerickhouse, Rod [6 ]
机构：
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haem, Parkville, Vic 3050, Australia
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Australia
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] CLL Res Consortium, Moores UCSD Canc Ctr, La Jolla, CA USA
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1089 / 1090
页数：2
相关论文
共 50 条
  • [1] An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Roberts, Andrew W.
    Seymour, John F.
    Brown, Jennifer R.
    Wierda, William G.
    Kipps, Thomas J.
    Carney, Dennis
    Xiong, Hao
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Krivoshik, Andrew
    Humerickhouse, Rod
    BLOOD, 2009, 114 (22) : 364 - 364
  • [2] ONGOING PHASE 1 STUDIES OF ABT-263; PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
    Brown, J.
    Roberts, A.
    Seymour, J. F.
    Wierda, W.
    O'Connor, O.
    Czuczman, M.
    Xiong, H.
    Enschede, S.
    Krivoshik, A.
    Wilson, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 229 - 229
  • [3] PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF ABT-263 IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
    Wierda, G.
    Roberts, P.
    Brown, R.
    Wilson, H.
    O'Connor, A.
    Czuczman, S.
    Busman, A.
    Xiong, H.
    Krivoshik, P.
    Enschede, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 138 - 138
  • [4] ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Wilson, W.
    O'Connor, O. O.
    Roberts, A. W.
    Czuczman, M.
    Brown, J.
    Xiong, H.
    Xiong, H.
    Chiu, Y.
    Krivoshik, A.
    Enschede, S.
    Humerickhouse, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [6] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [7] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [8] A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies
    Wilson, W. H.
    Czuczman, M. S.
    LaCasce, A. S.
    Gerecitano, J. F.
    Leonard, J. P.
    Dunleavy, K.
    Krivoshik, A. P.
    Xiong, H.
    Chiu, Y.
    O'Connor, O. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A phase 1 study evaluating the safety, PK & efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies
    O'Connor, O.
    Czuczman, M. S.
    LaCasce, A.
    Gerecitano, J.
    Leonard, J. P.
    Dunleavy, K.
    Krivoshik, A.
    Shovlin, M.
    Narwal, A.
    Xiong, H.
    Chiu, Y.
    Wilson, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 115 - 116
  • [10] Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.
    Wilson, Wyndham H.
    O'Connor, Owen A.
    Czuczman, Myron S.
    LaCasce, Ann
    Gerecitano, John
    Leonard, John P.
    Tulpule, Anil
    Xiong, Hao
    Chiu, Yi-Lin
    Busman, Todd
    Enschede, Sari
    Krivoshik, Andrew
    Humerickhouse, Rod
    BLOOD, 2009, 114 (22) : 682 - 682
12345